EP Patent

EP3672939A1 — Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate

Assigned to Celgene Corp · Expires 2020-07-01 · 6y expired

What this patent protects

The invention relates to processes for preparing ( S ) -tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, enantiomeric mixture or isotopologue thereof. The invention also relates to solid forms of various intermediates and products obtained from t…

USPTO Abstract

The invention relates to processes for preparing ( S ) -tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, enantiomeric mixture or isotopologue thereof. The invention also relates to solid forms of various intermediates and products obtained from the processes.

Drugs covered by this patent

Patent Metadata

Patent number
EP3672939A1
Jurisdiction
EP
Classification
—
Expires
2020-07-01
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.